PeopleBio
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
PeopleBio develops blood-based diagnostic tests designed to detect Alzheimer's disease at an early stage, before severe cognitive decline sets in.
Its products are intended for use in clinical and research settings where identifying the disease's biological markers, particularly amyloid proteins in the brain, is needed to guide treatment decisions. The company is listed on KOSDAQ, South Korea's technology and small-cap stock exchange, and its work centers on a single disease area: the early diagnosis of Alzheimer's through biomarker testing.
Summary is AI-generated and may contain errors · figures from DART filings
PeopleBio in five facts
What does PeopleBio do?
PeopleBio develops blood-based diagnostic tests designed to detect Alzheimer's disease at an early stage, before severe cognitive decline sets in.
Where is PeopleBio listed and in which sector?
PeopleBio (Korean name: 피플바이오) trades under KRX code 304840 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is PeopleBio?
Its market capitalisation was US$10.3M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were PeopleBio's latest annual revenue and operating profit?
For fiscal year 2025, PeopleBio reported revenue of US$2.2M, an operating loss of US$6.3M and a net loss of US$12.8M, per its annual report on DART (data retrieved from DART on 2026-10-02). Revenue was down 23.6% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-10-02
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- [Amended] DisclosureOct 21
- Report on large shareholdings (5% rule) (standard)Oct 8
- Report on large shareholdings (5% rule) (standard)Oct 8
- DisclosureSep 28
- [Amended] DisclosureSep 22
- [Amended] DisclosureSep 11
- DisclosureSep 11
- Completion report on merger, etc. (asset transfer)
TimeX AI Co., Ltd. (formerly PeopleBio) completed on August 14, 2026 its acquisition of land and buildings at 939-24, 939-30 and 939-11 Daechi-dong, Gangnam-gu, Seoul from Human Data Co., Ltd. for US$69.4M, under an asset-transfer agreement originally disclosed December 23, 2025 and amended via a change agreement executed August 14, 2026.
M&A · Aug 14 - Trading suspension (share consolidation/split registration)
PeopleBio's common shares will be suspended from trading from 2026-08-03 until the day before the new share listing date, because of a share consolidation requiring a change to the electronic registration.
M&A · Jul 29 - Operating results (consolidated) (preliminary) (fair disclosure)
PeopleBio filed provisional (unaudited) consolidated results for Q2 2026: revenue of US$1.13M (+128% year on year) and an operating loss of US$465K.
Earnings · Jul 16 - [Amended] Material event report (rights offering)
PeopleBio updated the terms of a private placement (third-party allotment) to raise US$692K, about 7.3% of its market value.
Capital raise · May 6 - [Amended] Material event report (rights offering)
PeopleBio updated the terms of a private placement (third-party allotment) to raise US$681K, about 7.3% of its market value.
Capital raise · Apr 20 - [Amended] Material event report (rights offering)
PeopleBio updated the terms of a private placement (third-party allotment) to raise US$677K, about 7.3% of its market value.
Capital raise · Apr 17 - Material event report (rights offering)
PeopleBio disclosed a private placement (third-party allotment) to raise US$678K, about 7.3% of its market value.
Capital raise · Apr 15 - Securities issuance results (voluntary) (third-party placement)Capital raise · Mar 13
- [Amended] Material event report (rights offering)
PeopleBio updated the terms of a private placement (third-party allotment) to raise US$2.18M, about 23.5% of its market value.
Capital raise · Mar 13 - [Amended] Material event report (rights offering)
PeopleBio updated the terms of a private placement (third-party allotment) to raise US$2.78M, about 29.3% of its market value.
Capital raise · Feb 13 - [Amended] Material event report (rights offering)Capital raise · Jan 30